Roivant Announces New Phase 2b/3 Clinical Program for Brepocitinib
Roivant announced a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris, a highly morbid inflammatory scalp disorder affecting approximately 100,000 adults in the United States.
